marketcaparena
Search

    LGND

    LIGAND PHARMACEUTICALS INC

    Company overview

    Market capitalization
    —
    Employees
    47
    Latest publication
    2026-09-29
    About LIGAND PHARMACEUTICALS INC

    Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USDQ1 20242024-03-31 · USD
    Total Revenue63,693,000USD51,722,000USD59,666,000USD115,461,000USD47,627,000USD51,812,000USD41,531,000USD30,978,000USD
    Research Development14,668,000USD2,148,000USD3,511,000USD21,019,000USD6,567,000USD5,675,000USD5,354,000USD5,971,000USD
    Selling General Administrative29,123,000USD20,836,000USD25,027,000USD28,446,000USD20,175,000USD24,475,000USD17,623,000USD10,951,000USD
    General And Administrative Expenses29,123,000USD———————
    Total Operating Expenses43,791,000USD32,279,000USD65,614,500USD35,710,000USD36,276,000USD36,174,000USD75,957,000USD16,922,000USD
    Operating Income8,591,000USD17,368,000USD20,040,000USD54,931,000USD8,444,000USD3,143,000USD-19,100,000USD2,988,000USD
    Total Other Income Expense Net55,713,000USD-41,627,000USD36,740,000USD86,206,000USD2,779,000USD-9,482,000USD-46,290,000USD110,459,000USD
    Interest Income7,298,000USD6,655,000USD6,393,000USD3,874,000USD1,621,000USD1,347,000USD2,757,000USD2,020,000USD
    Interest Expense1,748,000USD1,747,000USD1,785,000USD910,000USD1,153,000USD741,000USD1,268,000USD141,000USD
    Income Before Tax64,304,000USD-24,259,000USD56,780,000USD141,137,000USD11,223,000USD-6,339,000USD-65,390,000USD113,447,000USD
    Income Tax Expense15,796,000USD-10,914,000USD11,996,000USD23,864,000USD6,376,000USD833,000USD-13,479,000USD27,308,000USD
    Net Income48,508,000USD-13,345,000USD44,784,000USD117,273,000USD4,847,000USD-7,172,000USD-51,911,000USD86,139,000USD
    Cost Of Revenue—2,075,000USD-25,988,500USD24,820,000USD2,907,000USD12,495,000USD-15,326,000USD11,068,000USD
    Gross Profit—49,647,000USD85,654,500USD90,641,000USD44,720,000USD39,317,000USD56,857,000USD19,910,000USD
    Unclassified Operating Expenses—9,295,000USD37,076,500USD-13,755,000USD9,534,000USD6,024,000USD51,480,000USD—
    Net Interest Income—4,908,000USD4,608,000USD2,964,000USD468,000USD606,000USD1,489,000USD1,879,000USD
    Tax Provision—-10,914,000USD11,996,000USD23,864,000USD6,376,000USD833,000USD-13,479,000USD27,308,000USD
    Net Income From Continuing Ops—-13,345,000USD44,784,000USD117,273,000USD4,847,000USD-7,172,000USD-51,911,000USD86,139,000USD
    Ebit—-22,512,000USD56,780,000USD141,137,000USD12,376,000USD-5,598,000USD-64,122,000USD113,588,000USD
    Ebitda—-14,296,000USD66,404,000USD149,232,000USD20,898,000USD3,396,000USD-55,269,000USD122,353,000USD
    Depreciation And Amortization—8,216,000USD9,624,000USD8,095,000USD8,522,000USD8,994,000USD8,853,000USD8,765,000USD
    Reconciled Depreciation—8,216,000USD8,214,000USD8,269,000USD8,522,000USD8,994,000USD8,853,000USD8,765,000USD
    Selling And Marketing Expenses——————1,500,000USD—
    Source0000886163-26-000044DeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USDFY 20162016-12-31 · USDFY 20152015-12-31 · USD
    Total Revenue268,087,000USD196,245,000USD241,544,000USD163,562,000USD251,453,000USD141,102,000USD108,973,000USD71,914,000USD
    Cost Of Revenue6,587,500USD52,827,000USD62,176,000USD30,419,000USD6,337,000USD5,366,000USD5,571,000USD5,807,000USD
    Gross Profit261,499,500USD143,418,000USD179,368,000USD133,143,000USD245,116,000USD135,736,000USD103,402,000USD66,107,000USD
    Research Development81,182,000USD36,082,000USD32,105,000USD40,503,000USD27,863,000USD26,887,000USD21,221,000USD13,380,000USD
    Selling General Administrative92,449,000USD70,062,000USD46,790,000USD60,012,000USD37,734,000USD28,653,000USD26,621,000USD24,378,000USD
    Unclassified Operating Expenses40,669,500USD34,237,000USD-3,378,000USD-4,872,000USD15,792,000USD12,120,000USD10,643,000USD—
    Total Operating Expenses214,300,500USD140,381,000USD75,517,000USD95,643,000USD81,389,000USD67,660,000USD58,485,000USD37,758,000USD
    Operating Income47,199,000USD3,037,000USD103,851,000USD37,500,000USD163,727,000USD68,076,000USD43,885,000USD27,329,000USD
    Interest Income13,659,000USD2,046,000USD886,000USD8,078,000USD13,999,000USD13,448,000USD35,310,000USD16,945,000USD
    Interest Expense4,715,000USD1,799,000USD19,619,000USD27,415,000USD48,276,000USD11,400,000USD12,178,000USD11,802,000USD
    Net Interest Income8,944,000USD247,000USD-18,740,000USD-19,342,000USD-34,277,000USD-11,400,000USD-12,178,000USD—
    Income Before Tax158,960,000USD36,011,000USD72,205,000USD1,292,000USD173,330,000USD57,231,000USD7,960,000USD35,329,000USD
    Income Tax Expense34,507,000USD41,230,000USD-4,148,000USD-5,306,000USD30,009,000USD44,675,000USD10,327,000USD-219,596,000USD
    Tax Provision34,507,000USD41,230,000USD-10,288,000USD-7,553,000USD30,009,000USD44,675,000USD10,327,000USD-192,115,000USD
    Net Income124,453,000USD-33,361,000USD57,138,000USD-2,985,000USD143,321,000USD12,556,000USD-1,636,000USD257,305,000USD
    Net Income From Continuing Ops124,453,000USD-5,219,000USD57,586,000USD-2,985,000USD143,321,000USD12,556,000USD-2,367,000USD227,444,000USD
    Ebit158,960,000USD37,810,000USD91,824,000USD28,707,000USD221,606,000USD68,631,000USD43,885,000USD27,329,000USD
    Ebitda192,735,000USD81,204,000USD142,770,000USD56,673,000USD238,298,000USD81,151,000USD55,175,000USD29,956,000USD
    Depreciation And Amortization33,775,000USD43,394,000USD50,946,000USD27,966,000USD16,692,000USD12,520,000USD11,290,000USD2,627,000USD
    Reconciled Depreciation33,775,000USD34,237,000USD47,167,000USD27,966,000USD14,718,000USD11,714,000USD——
    Total Other Income Expense Net111,761,000USD32,974,000USD-31,646,000USD-36,208,000USD9,603,000USD-10,845,000USD-35,925,000USD8,000,000USD
    Discontinued Operations—-28,142,000USD-19,215,000USD-9,583,000USD——731,000USD731,000USD
    Net Income Applicable To Common Shares—-33,361,000USD57,586,000USD-2,985,000USD143,321,000USD12,556,000USD-1,636,000USD229,824,000USD
    Non Operating Income Net Other——-11,971,000USD-8,963,000USD57,879,000USD555,000USD-23,747,000USD19,802,000USD
    Minority Interest———0USD———-2,380,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets2,185,875,000USD1,532,105,000USD1,560,637,000USD1,476,772,000USD948,604,000USD905,435,000USD941,774,000USD954,866,000USD
    Cash And Equivalents1,006,702,000USD———————
    Cash And Short Term Investments1,357,758,000USD779,405,000USD733,521,000USD664,522,000USD255,296,000USD208,901,000USD256,165,000USD219,643,000USD
    Short Term Investments351,056,000USD664,328,000USD558,594,000USD525,146,000USD187,627,000USD160,912,000USD183,858,000USD156,024,000USD
    Total Current Assets1,457,116,000USD865,415,000USD832,271,000USD753,920,000USD352,945,000USD309,316,000USD331,559,000USD309,388,000USD
    Other Current Assets6,191,000USD17,946,000USD28,577,000USD19,402,000USD42,644,000USD45,770,000USD18,831,000USD34,174,000USD
    Other Non Current Assets11,841,000USD———————
    Total Liabilities1,218,359,000USD———————
    Total Current Liabilities46,736,000USD40,667,000USD37,447,000USD30,539,000USD64,734,000USD58,683,000USD37,112,000USD24,772,000USD
    Other Current Liabilities955,000USD———————
    Other Non Current Liabilities17,216,000USD———————
    Total Stockholder Equity967,516,000USD997,322,000USD1,017,212,000USD950,171,000USD828,529,000USD795,534,000USD830,439,000USD841,178,000USD
    Total Equity Including Noncontrolling Interest967,516,000USD———————
    Deferred Revenue621,000USD———————
    Net Receivables67,011,000USD54,798,000USD61,047,000USD58,096,000USD42,116,000USD42,831,000USD42,449,000USD42,131,000USD
    Inventory10,263,000USD13,266,000USD9,126,000USD11,900,000USD12,889,000USD11,814,000USD14,114,000USD13,440,000USD
    Property Plant Equipment Net9,836,000USD10,278,000USD10,794,000USD11,075,000USD11,623,000USD10,492,000USD24,806,000USD25,191,000USD
    Goodwill101,541,000USD———————
    Intangible Assets209,244,000USD410,877,000USD422,315,000USD233,535,000USD250,133,000USD258,391,000USD266,648,000USD274,905,000USD
    Accounts Payable9,405,000USD5,264,000USD3,238,000USD27,763,000USD8,584,000USD5,366,000USD5,233,000USD4,694,000USD
    Short Term Debt1,082,000USD1,088,000USD1,095,000USD2,178,000USD1,113,000USD883,000USD1,290,000USD1,090,000USD
    Common Stock20,000USD20,000USD20,000USD20,000USD20,000USD20,000USD20,000USD19,000USD
    Retained Earnings583,251,000USD594,743,000USD608,088,000USD578,215,000USD461,380,000USD456,533,000USD498,984,000USD530,072,000USD
    Accumulated Other Comprehensive Income4,476,000USD5,390,000USD8,455,000USD9,322,000USD8,494,000USD-1,563,000USD-5,942,000USD1,746,000USD
    Total Liab—534,783,000USD543,425,000USD526,601,000USD120,075,000USD109,901,000USD111,335,000USD113,688,000USD
    Other Current Liab—31,801,000USD31,254,000USD463,000USD52,955,000USD44,322,000USD27,491,000USD15,107,000USD
    Capital Stock—20,000USD20,000USD20,000USD20,000USD20,000USD20,000USD19,000USD
    Good Will—101,541,000USD101,541,000USD101,541,000USD101,541,000USD101,541,000USD105,250,000USD105,250,000USD
    Cash—115,077,000USD174,927,000USD139,376,000USD67,669,000USD47,989,000USD72,307,000USD63,619,000USD
    Current Deferred Revenue—621,000USD621,000USD135,000USD732,000USD722,000USD1,899,000USD1,773,000USD
    Net Debt—336,900,000USD276,564,000USD311,621,000USD-61,927,000USD-43,541,000USD-65,202,000USD-56,262,000USD
    Short Long Term Debt Total—451,977,000USD451,491,000USD450,997,000USD5,742,000USD4,448,000USD7,105,000USD7,357,000USD
    Long Term Debt—446,896,000USD446,192,000USD445,493,000USD————
    Long Term Investments—312,821,000USD364,828,000USD355,053,000USD204,464,000USD199,228,000USD195,932,000USD212,404,000USD
    Property Plant Equipment Gross—10,278,000USD17,372,000USD11,075,000USD11,623,000USD10,492,000USD33,074,000USD25,191,000USD
    Common Stock Shares Outstanding—19,883,000shares21,138,000shares20,170,000shares19,926,000shares19,191,000shares18,974,000shares18,419,000shares
    Non Current Assets Total—666,690,000USD728,366,000USD722,852,000USD595,659,000USD596,119,000USD610,215,000USD645,478,000USD
    Non Current Liabilities Total—494,116,000USD505,977,999USD496,062,000USD55,341,000USD51,218,000USD74,223,000USD88,916,000USD
    Non Current Liabilities Other—20,613,000USD19,563,000USD23,481,000USD18,466,000USD18,274,000USD17,700,000USD3,932,000USD
    Non Currrent Assets Other—2,709,000USD1,788,000USD325,175,000USD27,069,000USD25,921,000USD17,507,000USD27,650,000USD
    Net Working Capital—824,748,000USD794,824,000USD723,381,000USD288,211,000USD250,633,000USD294,447,000USD284,616,000USD
    Unclassified Non Current Assets—-171,536,000USD-172,900,000USD-303,527,000USD————
    Unclassified Current Liabilities—1,893,000USD1,239,000USD—1,350,000USD7,390,000USD1,199,000USD2,108,000USD
    Unclassified Non Current Liabilities—26,607,000USD40,222,999USD27,088,000USD36,875,000USD32,944,000USD56,523,000USD84,984,000USD
    Unclassified Equity—397,149,000USD400,629,000USD362,594,000USD358,615,000USD340,524,000USD337,357,000USD309,322,000USD
    Source0000886163-26-000044DeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets1,560,637,000USD941,774,000USD787,216,000USD762,668,000USD1,297,590,000USD1,362,285,000USD1,494,915,000USD1,260,803,000USD
    Intangible Assets422,315,000USD266,648,000USD299,606,000USD352,637,000USD386,801,000USD606,309,000USD230,538,000USD31,460,000USD
    Other Current Assets28,577,000USD18,831,000USD3,839,000USD3,399,000USD4,671,000USD3,822,000USD4,734,000USD40,378,000USD
    Total Liab543,425,000USD111,335,000USD86,303,000USD165,183,000USD476,431,000USD652,760,000USD727,683,000USD699,889,000USD
    Total Stockholder Equity1,017,212,000USD830,439,000USD700,913,000USD597,485,000USD821,159,000USD709,525,000USD767,232,000USD560,914,000USD
    Other Current Liab31,254,000USD27,491,000USD12,102,000USD15,117,000USD31,195,000USD58,414,000USD11,188,000USD48,347,000USD
    Common Stock20,000USD20,000USD18,000USD17,000USD17,000USD16,000USD17,000USD21,000USD
    Capital Stock20,000USD20,000USD18,000USD17,000USD17,000USD16,000USD17,000USD21,000USD
    Retained Earnings608,088,000USD498,984,000USD503,016,000USD450,862,000USD449,090,000USD391,952,000USD400,105,000USD-229,197,000USD
    Good Will101,541,000USD105,250,000USD103,370,000USD105,673,000USD105,673,000USD189,662,000USD95,229,000USD306,439,000USD
    Cash174,927,000USD72,307,000USD22,954,000USD45,006,000USD19,522,000USD47,619,000USD71,543,000USD718,381,000USD
    Cash And Short Term Investments733,521,000USD256,165,000USD170,309,000USD211,870,000USD341,108,000USD411,186,000USD1,069,867,000USD764,572,000USD
    Total Current Assets832,271,000USD331,559,000USD237,429,000USD263,601,000USD464,751,000USD500,559,000USD1,123,645,000USD870,540,000USD
    Total Current Liabilities37,447,000USD37,112,000USD16,782,000USD98,810,000USD41,665,000USD100,111,000USD17,002,000USD82,249,000USD
    Current Deferred Revenue621,000USD1,899,000USD1,843,000USD976,000USD654,000USD29,435,000USD2,139,000USD3,286,000USD
    Net Debt276,564,000USD-65,202,000USD-16,789,000USD42,740,000USD304,864,000USD408,795,000USD578,641,000USD-82,084,000USD
    Short Term Debt1,095,000USD1,290,000USD410,000USD77,410,000USD1,413,000USD8,478,000USD1,255,000USD26,433,000USD
    Short Long Term Debt Total451,491,000USD7,105,000USD6,165,000USD87,746,000USD324,386,000USD456,414,000USD650,184,000USD636,297,000USD
    Long Term Debt446,192,000USD———320,717,000USD442,293,000USD638,959,000USD609,864,000USD
    Long Term Investments364,828,000USD195,932,000USD48,321,000USD3,000,000USD———0USD
    Short Term Investments558,594,000USD183,858,000USD147,355,000USD166,864,000USD321,586,000USD363,567,000USD998,324,000USD46,191,000USD
    Net Receivables61,047,000USD42,449,000USD39,312,000USD35,038,000USD91,646,000USD59,064,000USD41,748,000USD55,850,000USD
    Inventory9,126,000USD14,114,000USD23,969,000USD13,294,000USD27,326,000USD26,487,000USD7,296,000USD7,124,000USD
    Accounts Payable3,238,000USD5,233,000USD2,427,000USD5,307,000USD8,403,000USD3,784,000USD2,420,000USD4,183,000USD
    Property Plant Equipment Net10,794,000USD24,806,000USD25,062,000USD27,491,000USD32,602,000USD37,168,000USD17,622,000USD5,372,000USD
    Property Plant Equipment Gross17,372,000USD33,074,000USD31,717,000USD15,009,000USD32,749,000USD21,326,000USD17,538,000USD5,372,000USD
    Accumulated Other Comprehensive Income8,455,000USD-5,942,000USD-817,000USD-984,000USD-917,000USD-801,000USD-216,000USD-1,024,000USD
    Common Stock Shares Outstanding20,294,000shares18,290,000shares17,757,000shares16,868,000shares17,246,000shares16,185,000shares19,757,000shares24,067,000shares
    Non Current Assets Total728,366,000USD610,215,000USD549,787,000USD499,067,000USD832,839,000USD861,726,000USD371,270,000USD390,263,000USD
    Non Current Liabilities Total505,977,999USD74,223,000USD69,521,000USD66,373,000USD434,766,000USD552,649,000USD710,681,000USD617,640,000USD
    Non Current Liabilities Other19,563,000USD17,700,000USD2,961,000USD25,422,000USD39,459,000USD45,758,000USD38,785,000USD7,776,000USD
    Non Currrent Assets Other1,788,000USD202,531,000USD9,923,000USD1,736,000USD272,034,000USD4,267,000USD2,273,000USD-600,746,000USD
    Net Working Capital794,824,000USD294,447,000USD220,647,000USD164,791,000USD423,086,000USD400,448,000USD1,106,643,000USD788,291,000USD
    Unclassified Non Current Assets-172,900,000USD-184,952,000USD63,505,000USD—-23,048,000USD-37,980,000USD——
    Unclassified Current Liabilities1,239,000USD1,199,000USD—-76,695,000USD———-26,433,000USD
    Unclassified Non Current Liabilities40,222,999USD56,523,000USD66,560,000USD-15,081,000USD-86,383,000USD-104,713,000USD-61,752,000USD-7,776,000USD
    Unclassified Equity400,629,000USD337,357,000USD198,678,000USD147,573,000USD372,952,000USD318,342,000USD367,309,000USD791,093,000USD
    Other Liab———56,032,000USD101,878,000USD104,713,000USD61,752,000USD7,776,000USD
    Other Assets———13,266,000USD58,777,000USD62,300,000USD27,965,000USD46,992,000USD
    Short Long Term Debt———76,695,000USD———26,433,000USD
    Net Tangible Assets———139,175,000USD76,523,000USD-86,446,000USD441,465,000USD223,015,000USD
    Deferred Long Term Liab————59,095,000USD64,598,000USD32,937,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation16,431,000USD
    Stock Based Compensation24,249,000USD
    Change To Account Receivables-7,441,000USD
    Change To Inventory-1,137,000USD
    Change To Liabilities5,960,000USD
    Change In Working Capital-2,618,000USD
    Operating Cash Flow72,709,000USD
    Capital Expenditures-254,000USD
    Net Investments-1,250,000USD
    Unclassified Investing Cash Flow228,274,000USD
    Investing Cash Flow226,770,000USD
    Net Debt Issuance-14,000USD
    Net Common Stock Issuance-82,075,000USD
    Unclassified Financing Cash Flow614,390,000USD
    Financing Cash Flow532,301,000USD
    Effect Of Forex Changes On Cash-5,000USD
    Change In Cash831,775,000USD
    End Cash Flow1,006,702,000USD
    Source0000886163-26-000044DeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-13,345,000USD44,784,000USD117,273,000USD4,847,000USD-42,451,000USD-31,088,000USD-7,172,000USD-51,911,000USD
    Depreciation8,216,000USD9,624,000USD6,859,000USD8,934,000USD9,341,000USD8,627,000USD7,287,000USD8,853,000USD
    Stock Based Compensation10,596,000USD14,270,000USD14,746,000USD9,997,000USD7,836,000USD7,524,000USD26,231,000USD11,060,000USD
    Other Non Cash Items37,339,000USD-23,279,000USD-124,017,000USD8,512,000USD21,606,000USD44,498,000USD12,805,000USD73,588,000USD
    Change To Account Receivables6,409,000USD-2,087,000USD-16,309,000USD-2,765,000USD-576,000USD-5,665,000USD4,793,000USD-9,049,000USD
    Change To Inventory-4,140,000USD2,774,000USD3,589,000USD-875,000USD-500,000USD2,566,000USD1,932,000USD2,489,000USD
    Change In Working Capital5,885,000USD9,289,000USD-10,615,000USD-6,171,000USD-5,168,000USD11,602,000USD-633,000USD-7,610,000USD
    Total Cash From Operating Activities48,691,000USD45,844,000USD13,090,000USD15,797,000USD-25,516,000USD28,471,000USD36,530,000USD13,314,000USD
    Capital Expenditures-228,000USD-9,000USD-15,000USD-214,000USD-214,000USD-712,000USD-14,241,000USD-2,139,000USD
    Free Cash Flow48,463,000USD45,835,000USD13,075,000USD15,583,000USD-25,730,000USD27,759,000USD22,289,000USD11,175,000USD
    Investments-101,098,000USD-14,790,000USD-353,445,000USD-10,667,000USD4,894,000USD-38,623,000USD-46,507,000USD-54,759,000USD
    Total Cashflows From Investing Activities-94,347,000USD-18,104,000USD-353,445,000USD-10,667,000USD4,894,000USD-38,623,000USD-46,507,000USD-54,759,000USD
    Net Borrowings-7,000USD6,903,000USD346,744,000USD-7,000USD-7,000USD-6,000USD-10,000USD—
    Total Cash From Financing Activities-14,133,000USD8,330,000USD409,645,000USD14,997,000USD-4,676,000USD20,388,000USD55,080,000USD9,491,000USD
    Change In Cash-59,833,000USD35,551,000USD71,707,000USD19,680,000USD-24,318,000USD8,688,000USD45,480,000USD-31,954,000USD
    Begin Period Cash Flow174,927,000USD139,376,000USD67,669,000USD47,989,000USD72,307,000USD63,619,000USD18,139,000USD50,093,000USD
    End Period Cash Flow115,094,000USD174,927,000USD139,376,000USD67,669,000USD47,989,000USD72,307,000USD63,619,000USD18,139,000USD
    Other Cashflows From Investing Activities7,410,000USD-8,418,000USD-14,761,000USD2,030,000USD-4,471,000USD-66,338,000USD-43,920,000USD-1,966,000USD
    Other Cashflows From Financing Activities-21,780,000USD-7,254,000USD-320,000USD6,764,999USD-8,891,000USD17,284,000USD33,695,000USD9,495,000USD
    Unclassified Financing Cash Flow7,654,000USD8,681,000USD78,221,000USD8,239,001USD4,222,000USD—21,395,000USD—
    Sale Purchase Of Stock—0USD-15,000,000USD—————
    Issuance Of Capital Stock—0USD———3,110,000USD——
    Unclassified Operating Cash Flow—-8,844,000USD8,844,000USD-10,322,000USD-16,680,000USD-12,692,000USD-1,988,000USD-20,666,000USD
    Unclassified Investing Cash Flow—5,113,000USD14,776,000USD-1,816,000USD4,685,000USD67,050,000USD58,161,000USD4,105,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income124,453,000USD-4,032,000USD52,154,000USD-33,361,000USD57,138,000USD-2,985,000USD629,302,000USD143,321,000USD
    Depreciation35,717,000USD35,239,000USD36,521,000USD51,370,000USD50,946,000USD27,966,000USD43,731,000USD14,718,000USD
    Stock Based Compensation46,849,000USD41,089,000USD25,743,000USD60,285,000USD38,783,000USD30,727,000USD24,515,000USD20,846,000USD
    Other Non Cash Items-120,830,000USD21,195,000USD-42,135,000USD-26,844,000USD-7,287,000USD27,995,000USD-797,498,000USD24,289,000USD
    Change To Account Receivables-21,737,000USD-6,459,000USD-2,601,000USD55,319,000USD-28,616,000USD-26,061,000USD25,463,000USD-29,544,000USD
    Change To Inventory4,988,000USD9,619,000USD-10,870,000USD12,058,000USD-427,000USD-17,799,000USD-2,061,000USD-2,559,000USD
    Change In Working Capital-12,665,000USD19,356,000USD-34,402,000USD65,677,000USD-52,164,000USD-10,064,000USD-4,215,000USD-38,854,000USD
    Total Cash From Operating Activities49,359,000USD97,047,000USD49,577,000USD137,850,000USD78,798,000USD54,586,000USD-29,336,000USD194,059,000USD
    Capital Expenditures-452,000USD-19,640,000USD-53,849,000USD-17,923,000USD-8,761,000USD-4,458,000USD-2,553,000USD-11,887,000USD
    Free Cash Flow48,907,000USD77,407,000USD-4,272,000USD119,927,000USD70,037,000USD50,128,000USD-31,889,000USD182,172,000USD
    Investments-363,221,000USD-143,664,000USD-8,682,000USD163,624,000USD40,010,000USD615,671,000USD-326,817,000USD-405,526,000USD
    Total Cashflows From Investing Activities-377,322,000USD-143,664,000USD-11,682,000USD163,624,000USD30,523,000USD231,648,000USD466,918,000USD-423,269,000USD
    Net Borrowings353,633,000USD-25,000USD-76,899,000USD-261,003,000USD-164,948,000USD-222,209,000USD-27,323,000USD515,404,000USD
    Total Cash From Financing Activities428,223,000USD97,141,000USD-59,947,000USD-275,990,000USD-137,761,000USD-310,545,000USD-485,172,000USD328,585,000USD
    Sale Purchase Of Stock-15,000,000USD-5,136,000USD-4,547,000USD-8,236,000USD-18,446,000USD-77,998,000USD-453,048,000USD-122,868,000USD
    Issuance Of Capital Stock0USD37,140,000USD0USD0USD————
    Change In Cash102,620,000USD49,353,000USD-22,052,000USD25,484,000USD-28,440,000USD-24,311,000USD-47,507,000USD99,160,000USD
    Begin Period Cash Flow72,307,000USD22,954,000USD45,006,000USD19,522,000USD47,962,000USD72,273,000USD119,780,000USD20,620,000USD
    End Period Cash Flow174,927,000USD72,307,000USD22,954,000USD45,006,000USD19,522,000USD47,962,000USD72,273,000USD119,780,000USD
    Other Cashflows From Investing Activities-4,344,000USD-12,890,000USD-49,910,000USD-868,000USD-1,220,000USD3,258,000USD808,128,000USD3,914,000USD
    Other Cashflows From Financing Activities-9,773,000USD60,026,000USD-5,496,000USD-18,421,000USD-7,068,000USD-789,000USD-4,801,000USD-80,873,000USD
    Unclassified Operating Cash Flow-24,165,000USD-15,800,000USD11,696,000USD20,723,000USD-8,618,000USD-19,053,000USD74,829,000USD29,739,000USD
    Unclassified Investing Cash Flow-9,305,000USD32,530,000USD100,759,000USD18,791,000USD—-382,823,000USD-11,840,000USD-9,770,000USD
    Unclassified Financing Cash Flow99,363,000USD42,276,000USD26,995,000USD16,674,000USD68,018,000USD-6,532,000USD—16,922,000USD
    Change To Liabilities———-9,621,000USD-15,060,000USD-4,584,000USD-4,398,000USD-4,542,000USD
    Dividends Paid———-5,004,000USD-15,317,000USD-3,017,000USD-2,997,000USD—
    Cash And Cash Equivalents Changes————-28,440,000USD-24,311,000USD-47,590,000USD99,375,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2024Quarterly · 2024-03-31ProductContract And Revenue Income Other1,944,000USD0000886163-24-000032
    Q1 2024Quarterly · 2024-03-31ProductEvomela1,397,000USD0000886163-24-000032
    Q1 2024Quarterly · 2024-03-31ProductFilspari1,772,000USD0000886163-24-000032
    Q1 2024Quarterly · 2024-03-31ProductFinancial Royalty Assets738,000USD0000886163-24-000032
    Q1 2024Quarterly · 2024-03-31ProductKyprolis6,632,000USD0000886163-24-000032
    Q1 2024Quarterly · 2024-03-31ProductMaterial Sales Captisol9,212,000USD0000886163-24-000032
    Q1 2024Quarterly · 2024-03-31ProductMilestone And Other727,000USD0000886163-24-000032
    Q1 2024Quarterly · 2024-03-31ProductRoyalty Other2,176,000USD0000886163-24-000032
    Q1 2024Quarterly · 2024-03-31ProductRylaze2,952,000USD0000886163-24-000032
    Q1 2024Quarterly · 2024-03-31ProductTeriparatide Injection2,041,000USD0000886163-24-000032
    Q1 2024Quarterly · 2024-03-31ProductVaxneuvance1,387,000USD0000886163-24-000032
    FY 2023Yearly · 2023-12-31ProductContract Revenue — License Fees217,000USD0000886163-24-000009
    FY 2023Yearly · 2023-12-31ProductContract Revenue — License Fees Milestones And Other Product Other1,400,000USD0000886163-24-000009
    FY 2023Yearly · 2023-12-31ProductContract Revenue — Milestone16,800,000USD0000886163-24-000009
    FY 2023Yearly · 2023-12-31ProductContract Revenue — Services615,000USD0000886163-24-000009
    FY 2023Yearly · 2023-12-31ProductMaterial Sales Captisol COVID0USD0000886163-24-000009
    FY 2023Yearly · 2023-12-31ProductRoyalty Evomela10,212,000USD0000886163-24-000009
    FY 2023Yearly · 2023-12-31ProductRoyalty Kyprolis35,640,000USD0000886163-24-000009
    FY 2023Yearly · 2023-12-31ProductRoyalty Other41,849,000USD0000886163-24-000009
    FY 2023Yearly · 2023-12-31ProductRoyalty Rylaze13,520,000USD0000886163-24-000009
    FY 2023Yearly · 2023-12-31ProductRoyalty Teriparatide Injection11,061,000USD0000886163-24-000009
    Q3 2023Quarterly · 2023-09-30ProductContract And Revenue Income Other0USD0000886163-24-000078
    Q3 2023Quarterly · 2023-09-30ProductEvomela2,497,000USD0000886163-24-000078
    Q3 2023Quarterly · 2023-09-30ProductFilspari1,122,000USD0000886163-24-000078
    Q3 2023Quarterly · 2023-09-30ProductFinancial Royalty Assets25,000USD0000886163-24-000078
    Q3 2023Quarterly · 2023-09-30ProductIntangible Royalty Assets — Kyprolis10,537,000USD0000886163-24-000078
    Q3 2023Quarterly · 2023-09-30ProductIntangible Royalty Assets — Material Sales Captisol8,608,000USD0000886163-24-000078
    Q3 2023Quarterly · 2023-09-30ProductIntangible Royalty Assets — Teriparatide Injection2,800,000USD0000886163-24-000078
    Q3 2023Quarterly · 2023-09-30ProductRoyalty Other2,288,000USD0000886163-24-000078
    Q3 2023Quarterly · 2023-09-30ProductRylaze3,678,000USD0000886163-24-000078
    Q3 2023Quarterly · 2023-09-30ProductVaxneuvance1,313,000USD0000886163-24-000078
    Q2 2023Quarterly · 2023-06-30ProductContract Revenue — License Fees508,000USD0000886163-23-000050
    Q2 2023Quarterly · 2023-06-30ProductContract Revenue — License Fees Milestones And Product Other Product Other208,000USD0000886163-23-000050
    Q2 2023Quarterly · 2023-06-30ProductMaterial Sales Captisol COVID0USD0000886163-23-000050
    Q2 2023Quarterly · 2023-06-30ProductMilestone0USD0000886163-23-000050
    Q2 2023Quarterly · 2023-06-30ProductRoyalty — Evomela2,357,000USD0000886163-23-000050
    Q2 2023Quarterly · 2023-06-30ProductRoyalty — Kyprolis8,097,000USD0000886163-23-000050
    Q2 2023Quarterly · 2023-06-30ProductRoyalty — Rylaze3,028,000USD0000886163-23-000050
    Q2 2023Quarterly · 2023-06-30ProductRoyalty — Teriparatide Injection3,613,000USD0000886163-23-000050
    Q2 2023Quarterly · 2023-06-30ProductRoyalty Other8,555,000USD0000886163-23-000050
    Q1 2023Quarterly · 2023-03-31ProductContract Revenue — License Fees114,000USD0000886163-23-000027
    Q1 2023Quarterly · 2023-03-31ProductContract Revenue — License Fees Milestones And Product Other Product Other789,000USD0000886163-23-000027
    Q1 2023Quarterly · 2023-03-31ProductContract Revenue — Milestone15,300,000USD0000886163-23-000027
    Q1 2023Quarterly · 2023-03-31ProductMaterial Sales Captisol COVID0USD0000886163-23-000027
    Q1 2023Quarterly · 2023-03-31ProductRoyalty — Evomela2,550,000USD0000886163-23-000027
    Q1 2023Quarterly · 2023-03-31ProductRoyalty — Kyprolis6,228,000USD0000886163-23-000027
    Q1 2023Quarterly · 2023-03-31ProductRoyalty — Rylaze2,609,000USD0000886163-23-000027
    Q1 2023Quarterly · 2023-03-31ProductRoyalty — Teriparatide Injection3,500,000USD0000886163-23-000027
    Q1 2023Quarterly · 2023-03-31ProductRoyalty Other12,889,000USD0000886163-23-000027
    Q3 2022Quarterly · 2022-09-30ProductContract Revenue — License Fees Milestones And Product Other Product Other1,269,000USD0000886163-23-000086
    Q3 2022Quarterly · 2022-09-30ProductContract Revenue — Milestone2,658,000USD0000886163-23-000086
    Q3 2022Quarterly · 2022-09-30ProductContract Revenue — Services90,000USD0000886163-23-000086
    Q3 2022Quarterly · 2022-09-30ProductMaterial Sales Captisol Core3,582,000USD0000886163-23-000086
    Q3 2022Quarterly · 2022-09-30ProductMaterial Sales Captisol COVID32,367,000USD0000886163-23-000086
    Q3 2022Quarterly · 2022-09-30ProductRoyalty — Evomela3,123,000USD0000886163-23-000086
    Q3 2022Quarterly · 2022-09-30ProductRoyalty — Kyprolis9,123,000USD0000886163-23-000086
    Q3 2022Quarterly · 2022-09-30ProductRoyalty — Rylaze2,099,000USD0000886163-23-000086
    Q3 2022Quarterly · 2022-09-30ProductRoyalty — Teriparatide Injection4,071,000USD0000886163-23-000086
    Q3 2022Quarterly · 2022-09-30ProductRoyalty Other839,000USD0000886163-23-000086
    Q3 2022Quarterly · 2022-09-30SegmentLigand Core Business59,221,000USD0000886163-22-000135
    Q3 2022Quarterly · 2022-09-30SegmentOmni Ab Technologies6,867,000USD0000886163-22-000135
    Q2 2022Quarterly · 2022-06-30SegmentLigand Core Business50,127,000USD0000886163-22-000117
    Q2 2022Quarterly · 2022-06-30SegmentOmni Ab Technologies7,292,000USD0000886163-22-000117
    Q1 2022Quarterly · 2022-03-31ProductContract Revenue — License Fees2,081,000USD0000886163-23-000027
    Q1 2022Quarterly · 2022-03-31ProductContract Revenue — License Fees Milestones And Product Other Product Other2,888,000USD0000886163-23-000027
    Q1 2022Quarterly · 2022-03-31ProductContract Revenue — Milestone5,993,000USD0000886163-23-000027
    Q1 2022Quarterly · 2022-03-31ProductMaterial Sales Captisol Core6,226,000USD0000886163-23-000027
    Q1 2022Quarterly · 2022-03-31ProductMaterial Sales Captisol COVID5,896,000USD0000886163-23-000027
    Q1 2022Quarterly · 2022-03-31ProductRoyalty — Evomela2,701,000USD0000886163-23-000027
    Q1 2022Quarterly · 2022-03-31ProductRoyalty — Kyprolis4,622,000USD0000886163-23-000027
    Q1 2022Quarterly · 2022-03-31ProductRoyalty — Rylaze1,649,000USD0000886163-23-000027
    Q1 2022Quarterly · 2022-03-31ProductRoyalty — Teriparatide Injection2,911,000USD0000886163-23-000027
    Q1 2022Quarterly · 2022-03-31ProductRoyalty Other1,549,000USD0000886163-23-000027
    Q1 2022Quarterly · 2022-03-31SegmentLigand Core Business36,515,000USD0000886163-22-000049
    Q1 2022Quarterly · 2022-03-31SegmentOmni Ab Technologies9,178,000USD0000886163-22-000049
    Q3 2021Quarterly · 2021-09-30ProductContract Revenue — License Fees200,000USD0000886163-22-000135
    Q3 2021Quarterly · 2021-09-30ProductContract Revenue — License Fees Milestones And Product Other Product Other1,647,000USD0000886163-22-000135
    Q3 2021Quarterly · 2021-09-30ProductContract Revenue — Milestone7,419,000USD0000886163-22-000135
    Q3 2021Quarterly · 2021-09-30ProductContract Revenue Service4,828,000USD0000886163-22-000135
    Q3 2021Quarterly · 2021-09-30ProductMaterial Sales Captisol Core5,374,000USD0000886163-22-000135
    Q3 2021Quarterly · 2021-09-30ProductMaterial Sales Captisol COVID29,719,000USD0000886163-22-000135
    Q3 2021Quarterly · 2021-09-30ProductRoyalty — Evomela2,665,000USD0000886163-22-000135
    Q3 2021Quarterly · 2021-09-30ProductRoyalty — Kyprolis8,821,000USD0000886163-22-000135
    Q3 2021Quarterly · 2021-09-30ProductRoyalty — Rylaze600,000USD0000886163-22-000135
    Q3 2021Quarterly · 2021-09-30ProductRoyalty — Teriparatide Injection2,567,000USD0000886163-22-000135
    Q3 2021Quarterly · 2021-09-30ProductRoyalty Other995,000USD0000886163-22-000135
    Q3 2021Quarterly · 2021-09-30SegmentLigand Core Business59,695,000USD0000886163-22-000135
    Q3 2021Quarterly · 2021-09-30SegmentOmni Ab Technologies5,140,000USD0000886163-22-000135
    Q2 2021Quarterly · 2021-06-30ProductContract Revenue — License Fees1,050,000USD0000886163-22-000117
    Q2 2021Quarterly · 2021-06-30ProductContract Revenue — License Fees Milestones And Product Other Product Other1,540,000USD0000886163-22-000117
    Q2 2021Quarterly · 2021-06-30ProductContract Revenue — Milestone3,600,000USD0000886163-22-000117
    Q2 2021Quarterly · 2021-06-30ProductContract Revenue Service7,360,000USD0000886163-22-000117
    Q2 2021Quarterly · 2021-06-30ProductMaterial Sales Captisol Core9,682,000USD0000886163-22-000117
    Q2 2021Quarterly · 2021-06-30ProductMaterial Sales Captisol COVID52,827,000USD0000886163-22-000117
    Q2 2021Quarterly · 2021-06-30ProductRoyalty — Evomela2,193,000USD0000886163-22-000117
    Q2 2021Quarterly · 2021-06-30ProductRoyalty — Kyprolis5,440,000USD0000886163-22-000117
    Q2 2021Quarterly · 2021-06-30ProductRoyalty — Teriparatide Injection264,000USD0000886163-22-000117
    Q2 2021Quarterly · 2021-06-30ProductRoyalty Other719,000USD0000886163-22-000117
    Q2 2021Quarterly · 2021-06-30ProductRylaze0USD0000886163-22-000117
    Q2 2021Quarterly · 2021-06-30SegmentLigand Core Business78,854,000USD0000886163-22-000117

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.